An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

This study is testing a radioactive drug treatment called lutetium-177 oxodotreotide — which seeks out and targets neuroendocrine tumors — in people with advanced gastrointestinal or pancreatic neuroendocrine tumors that cannot be surgically removed. **You may be eligible if...** - You are between 18 and 75 years old - You have been confirmed by biopsy to have a low-to-intermediate grade (G1 or G2) gastrointestinal or pancreatic neuroendocrine tumor - Your tumor cannot be surgically removed and has spread locally or to other parts of the body - Your general health is good (ECOG 0 or 1) **You may NOT be eligible if...** - You have known cancer spread to the brain (unless previously treated and stable for at least 24 weeks) - You have poorly controlled heart disease or diabetes - You have severe kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.